Our expertise in translational pharmacology

Translational pharmacology is the bridge enabling an effective transition between pre-clinical and clinical phases. Rather than working on any type of pharmacology in an animal or cellular model, the work is performed directly on human tissue. This brings vital information on would be the clinical reality in terms of the pharmacology. While it does not provide information about the Mode of Action, it will give you an excellent understanding of the result you would receive once you are treating the patient.

Translational pharmacology informs drug developers of the dangers they may eventually encounter with a lead compound, in terms of potential toxicity, when they progress from pre-clinical to clinical. It also provides information about what would be the success biomarkers and all the markers needed to choose the right patient and provide the right therapeutic window. The approach also offers the possibility of monitoring a project’s critical development path.

Advantages of a translational pharmacology approach

Inoviem highly recommends adopting a translational pharmacology strategy in making the bridge between pre-clinical and clinical phases at the inception of any project, as it saves time and money:

  • Discover as soon as possible rather than in five years whether or not your compound will work
  • Find out sooner than the standard seven years whether your project will pass phase II; you will already know which patients you can work on and what patient group would benefit from the new compound or new treatment
  • Achieve higher precision in your treatment because you will see the side-effects far sooner than waiting until phase III, 10 to 15 years into the project
  • Provide safety in terms of the development of the program (you can kill your program in year 1; no need to waste 10 years before reaching this conclusion)

How translational pharmacology works

Translational pharmacology enables us to work with the complexity of a project rather than simplifying the complexity to our level of understanding.

While other approaches modify the compound or the protein in order to work on it, e.g. adding a type of dye on the top to make things visible, we work directly on the native material in a label-free system. We do not change the compound or the molecule. Working directly on fresh human tissue in the physiological as well as the pathological environment, which reflects the clinical reality, allows us to work with the complexity of the native protein.

Since we change neither the nature of the tissue nor the compound, we can work in any therapeutic area.

How we work with clients

Clients turn to us when they need to fill a skill’s gap. If a project falters, unlike standard CROs that offer established, one-size fits all protocols, Inoviem develops new methodologies, approaches and/or technologies specifically tailored to solve each client’s unique problem.

This includes providing any biotech developing a compound with the key piece(s) of information needed to accomplish its fundraising. It also includes providing any pharma company developing a new program within any auto-immune disease program with the right model or right access to human tissue that it requires but is unable to access itself. In addition, we provide all the information related to the clinical study and patient material. Whenever there is a problem in a project, we can solve it.